Fresenius Medical Care AG (FMS)

NYSE: FMS · 实时价格 · USD

22.66

+0.19 (0.85%)

收盘价： Sep 04, 2026, 3:59 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

0.85% (1D)

买价	22.3
市值	12B
营收（TTM）	19.4B
净利润（TTM）	938M
	0.83
	1.92
	11.77
	6.19
市净率（TTM）	0.82
市销率（TTM）	0.62
财报日期	Nov 3, 2026

卖价	23.93
成交量	480,309
20日均量	669,456
开盘价	22.66
前收盘价	22.47
日内区间	22.56 - 22.78
52周区间	20.02 - 27.64
分析师	持有
目标价	24.91 (9.93%)
分红	$0.87 (3.85%)
除息日	May 22, 2026

关于 FMS

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient'...

[阅读更多]

行业 Medical Care Facilities

板块 Healthcare

上市日期 Sep 17, 1996

员工人数 107,226

交易所 NYSE

股票代码 FMS

官网 https://www.freseniusmedicalcare.com

公司完整简介

财务表现

2025年，Fresenius Medical Care的营收为19.63B，较上一年的19.34B增长1.51%。净利润为978.37M，增长81.88%。

财务报表

分析师预测

根据7位分析师的评级，FMS的平均评级为“Hold”。12个月目标价为24.91，较最新价格上涨空间9.93%。

股票预测

财报意外

Fresenius Medical Care 已于 Aug 3, 2026 发布季度财报：

营收为 n/a 低于预期 $0, ， -100.00% 同比下滑.
每股收益为 0.56 超出预期 0.06, ， 21.74% 同比增长.

下次财报发布时间

Fresenius Medical Care AG 的下次财报预计于 Nov 3, 2026, 盘中。
分析师预计营收为 ... 升级

股价变动原因

新闻

4天前 · Zacks

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

4天前 · Zacks

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.

3周前 · Motley Fool

Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript

U.S. referral execution gap offset by strong margin expansion and transformation savings.

1月前 · Zacks

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

1月前 · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Expands BEACON US To Build Its Case For HVHDF

Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and ...

第 1 页，共 2 页

Fresenius Medical Care AG (FMS)